FDA declines to grant approval for Gilead Sciences' HIV treatment
The US Food and Drug Administration (FDA) has declined to grant approval for Gilead Sciences’ investigational therapy lenacapavir for HIV.
Page 3 - Child Level Menu Hover News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Child Level Menu Hover. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Child Level Menu Hover Today - Breaking & Trending Today
ViiV Healthcare gets FDA nod for two-month dosing of Cabenuva
ViiV Healthcare has secured the US FDA approval for the expanded labelling of Cabenuva (cabotegravir, rilpivirine) to treat HIV-1 in adults.
Neogene Therapeutics signs global license agreement with NCI
Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio of T cell receptor (TCRs) targeting KRAS and TP53 mutations for the treatment of patients suffering with cancer.
AbbVie seeks approval for upadacitinib to treat nr-axSpA
Abbvie has submitted applications to the US FDA and the EMA to obtain approvals for upadacitinib (RINVOQ) to treat nr-axSpA.
Gerresheimer AG extends CEO Dietmar Siemssen's Contract by Five Years - Pharmaceutical Business review
At its meeting yesterday, the Supervisory Board of Gerresheimer AG extended the contract with CEO Dietmar Siemssen to the end of October 2026. Dietmar Siemssen has been CEO